Our updated CTP TUM Panel now includes a broader gene list and covers more than 780 cancer-associated genes, including 7 pharmacogenetically-relevant genes, and 39 therapy-relevant fusions.
Amongst the newly added genes are the pharmacogenetically-relevant genes CACNA1S and NUDT15, which play a pivotal role in anesthetic-induced malignant hyperthermia and drug-induced myelosuppression, respectively. This expansion allows researchers to gain deeper insights into genetic factors influencing drug response and therapy outcomes.
In addition, the number of therapy-relevant fusions analyzed at a high sequencing depth increased from 31 to 39. Thus, the breakpoint enrichment for DNA-based gene fusions is expanded.
With regular updates of our CTP TUM Panel, we incorporate the latest scientific knowledge and medical findings to keep our customers’ research up to date. These enhancements aim to provide even more precise and comprehensive insights into tumor biology.
For further details on our CTP TUM Panel, please visit our website or contact our team at rps@cegat.com.